Wednesday, July 29, 2026

argenx to acquire Forte Biosciences and expand immunology pipeline

argenx plans to acquire Forte Biosciences. Through the transaction, the company intends to add FB102 to its immunology pipeline. The asset is described as a first-in-class anti-CD122 antibody.

Immunology portfolio focus

The planned acquisition supports argenx’s strategy to broaden its activities in immunology. FB102 would add an antibody approach targeting CD122 to the company’s research and development pipeline.

No financial terms, regulatory details or transaction timeline were included in the information provided.